Accelerate Your Discovery with "Off-the-Shelf" Solutions
Tailored Screening Solutions Ready to Advance Your Research
At 48Hour Discovery, we understand that speed is of the essence in the competitive landscape of drug development. To support this need, we offer a unique Target Prescreening service that provides our clients with immediate access to a wealth of pre-screened data across a diverse array of cancer targets.
What is Target Pre-screening?
Target Prescreening is our proactive approach to peptide drug discovery. We continuously screen a broad spectrum of targets using our proprietary phage display platform. This process not only refines our library but creates an extensive database of actionable data that includes over 20 well-characterized targets to date, with an additional 16 targets currently being evaluated.
Benefits of Prescreening
- Speed to Discovery: Jumpstart your project with pre-screened targets that significantly cut down the initial phases of discovery.
- Data-Driven Decisions: Leverage our extensive data to make informed choices about which targets to pursue, reducing the risk and uncertainty in early-stage research.
- Cost Efficiency: Save on the costs associated with initial screenings. Access our findings and focus your resources on further development and optimization.
- Mitigate Early Discovery Risks: Leveraging our prescreened targets reduces uncertainties in the initial stages of drug discovery, enabling more predictable and successful outcomes.
Our Screening Process
Our screening process involves:
- Rigorous evaluation of targets using our advanced phage display technology and billion scale genetically encoded libraries.
- Deep exploration of initial hits in a robust, calibrated experiment
- Potential for chemical modification of libraries to include linkers and chelators, enhancing the relevance and applicability of findings.
- Thorough biophysical and bioinformatics analyses to ensure the quality and potential of identified peptides.
Available Targets and Data
Currently, our database includes a wide range of targets related to oncology, including but not limited to PD-L1, EpCAM, and ROR1. Each target comes with comprehensive binding enrichment data, specificity profiles, and preliminary affinity results.
Interested in Our Pre-screening Data?
If you are looking to expedite your peptide drug discovery projects and are interested in specific targets from our prescreening database, we invite you to get in touch. Our team is ready to discuss how our data can align with your research goals and help speed up your path to discovery.
